The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
The launch of the first biosimilar monoclonal antibody in the US, Pfizer Inc./Celltrion Inc.'s Inflectra (infliximab-dyyb), is raising questions about how biosimilar manufacturers can gain traction in the market when the innovator is willing to compete on price and play hard ball in contract negotiations with insurers – and payers are willing to shake on the deal.
Nearly one year after the launch of Inflectra, Johnson & Johnson's Remicade (infliximab) has held onto to the lion's...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
